- Condition: Stroke
Interventions: Behavioral: Usual care; Behavioral: Overground visual cue training; Behavioral: Treadmill visual cue training
Sponsors: University of Salford; University of Salford; University of Birmingham; Nottingham Clinical Trials Unit; Stroke Research Network; The University of Newcastle, Australia
Not yet recruiting - verified May 2012 - Condition: Stroke
Intervention: Behavioral: Gait training
Sponsors: Northeastern University; Northeastern University; Rosalind Franklin University of Medicine and Science; New England Rehabilitation Hospital
Recruiting - verified March 2012 - Conditions: Liver Cirrhosis; Fatty Liver
Intervention:
Sponsors: University of Oxford; University of Oxford; British Heart Foundation; Oxford University Hospitals NHS Trust
Recruiting - verified March 2012 - Condition: Alcoholism
Interventions: Other: Training and support (T&S); Other: Financial incentive; Other: E-SBI (online screening and brief intervention)
Sponsors: Fundacion Clinic per a la Recerca Biomédica; Fundacion Clinic per a la Recerca Biomédica; European Commission; Stichting Katholieke Universiteit; University of Newcastle Upon-Tyne; King's College London; Goeteborgs Universitet; Linkoeping University; Departament de Salut de la Generalitat de Catalunya; Panstwowa Agencja Rozwiazywania Problemow Alkoholowych; University College, London; Maastricht University; Pomorski Uniwersytet Medyczny w Szczecinie
Enrolling by invitation - verified December 2011 - Condition: Cardiovascular Injury
Intervention:
Sponsors: Health Effects Institute; Health Effects Institute; New England Research Institutes; University of California, San Francisco; University of North Carolina, Chapel Hill; University of Rochester
Not yet recruiting - verified November 2011 - Conditions: Burns; Smoke Inhalation Injury
Interventions: Behavioral: Injury Prevention Briefing Plus facilitation; Behavioral: Injury Prevention Briefing
Sponsors: University of Nottingham; University of Nottingham
Recruiting - verified October 2011 - Condition: Asthma
Interventions: Drug: Zithromax; Drug: Placebo
Sponsors: Imperial College London; Imperial College London; National Institute for Health Research, United Kingdom
Not yet recruiting - verified September 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: olaparib; Drug: temozolomide; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: diffusion-weighted magnetic resonance imaging; Procedure: dynamic contrast-enhanced magnetic resonance imaging; Procedure: therapeutic conventional surgery
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Chronic Obstructive Pulmonary Disease (COPD)
Intervention:
Sponsors: Centre for Research in Environmental Epidemiology, Spain; Centre for Research in Environmental Epidemiology, Spain; Katholieke Universiteit Leuven; University of Edinburgh; Royal Brompton & Harefield NHS Foundation Trust; University Medical Centre Groningen; University of Athens
Recruiting - verified October 2011 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: NG-nitro-L-arginine; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: computed tomography; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: Cancer Research UK; Cancer Research UK
Active, not recruiting - verified March 2012 - Condition: Head and Neck Cancer
Interventions: Drug: docetaxel; Drug: everolimus; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University College, London; University College, London
Terminated - verified December 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: aminolevulinic acid hydrochloride; Drug: polifeprosan 20 with carmustine implant; Drug: temozolomide; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Recruiting - verified May 2011 - Condition: HIV Infections
Intervention: Biological: CN54gp140 glycoprotein-hsp70 conjugate vaccine
Sponsors: St George's, University of London; St George's, University of London; European Union
Active, not recruiting - verified October 2011 - Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Drug: gefitinib; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Oncology Clinical Trials Office at University of Oxford
Recruiting - verified August 2011 - Conditions: Graft Versus Host Disease; Leukemia; Lymphoma
Interventions: Other: CD4 DLI; Other: No DLI
Sponsors: University College, London; University College, London
Recruiting - verified March 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: boron phenylalanine; Drug: mannitol; Other: biologic sample preservation procedure; Radiation: radiation therapy treatment planning/simulation
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified February 2012 - Condition: Leukemia
Interventions: Drug: hydroxychloroquine; Drug: imatinib mesylate; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University of Glasgow; Lynn McMahon; Medical Research Council; CRUK Trials unit Glasgow
Recruiting - verified November 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Biological: glioblastoma multiforme multipeptide vaccine IMA950; Biological: sargramostim; Drug: temozolomide; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Conditions: Breast Cancer; Colorectal Cancer; Gastric Cancer; Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes; Biological: aldesleukin; Drug: cyclophosphamide; Drug: fludarabine phosphate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Cancer Research UK; Cancer Research UK
Terminated - verified February 2012 - Condition: Lung Cancer
Interventions: Drug: pazopanib hydrochloride; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified July 2011 - Conditions: Male Erectile Disorder; Prostate Cancer; Therapy-related Toxicity; Urinary Incontinence
Interventions: Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: multiparametric magnetic resonance imaging; Procedure: quality-of-life assessment; Procedure: transperineal prostate biopsy; Procedure: transrectal prostate biopsy
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified November 2010 - Condition: Prostate Cancer
Interventions: Drug: dutasteride; Drug: gadolinium-chelate; Other: active surveillance; Procedure: diffusion-weighted magnetic resonance imaging; Procedure: functional magnetic resonance imaging; Procedure: prostate biopsy; Procedure: ultrasound imaging
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified August 2011 - Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer
Interventions: Drug: carboplatin; Drug: gemcitabine hydrochloride; Drug: vandetanib; Drug: Placebo
Sponsors: Wales Cancer Trials Unit; Wales Cancer Trials Unit; Cardiff University
Recruiting - verified March 2012 - Conditions: Gastric Cancer; Head and Neck Cancer; Lymphoma; Lymphoproliferative Disorder; Nonneoplastic Condition
Interventions: Biological: EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Cancer Research UK; Cancer Research UK
Completed - verified February 2012 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: angiogenesis inhibitor GSAO; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsors: Cancer Research UK; Cancer Research UK
Terminated - verified April 2012 - Condition: Prostate Cancer
Interventions: Dietary Supplement: C-11 choline; Radiation: 18F-fluoromethylcholine
Sponsors: Cancer Research UK; Cancer Research UK
Withdrawn - verified February 2012 - Condition: Coronary Artery Diseases
Intervention: Procedure: PCI
Sponsors: Harvard Clinical Research Institute; Harvard Clinical Research Institute; Brockton Hospital; Caritas Good Samaritan Medical Center; Caritas Norwood Hospital; Holy Family Hospital; Lawrence General Hospital; Lowell General Hospital; Melrose Wakefield Hospital; Metro West Medical Center; Saints Memorial Medical Center; South Shore Hospital
Active, not recruiting - verified November 2011 - Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Aurora B/C kinase inhibitor GSK1070916A; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: diffusion-weighted magnetic resonance imaging + PET CT; Radiation: fludeoxyglucose F 18 dynomic contrast
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: lapatinib ditosylate; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Institute of Cancer Research, United Kingdom
Recruiting - verified July 2011 - Condition: Pancreatic Cancer
Interventions: Drug: Notch signaling pathway inhibitor MK0752; Drug: gemcitabine hydrochloride; Other: imaging biomarker analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: fludeoxyglucose F 18
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified February 2012 - Condition: Kidney Cancer
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified September 2011 - Conditions: Chemotherapeutic Agent Toxicity; Fatigue; Lung Cancer; Musculoskeletal Complications
Interventions: Drug: carboplatin; Drug: vinorelbine tartrate; Other: neuromuscular electrical stimulation; Other: physiologic testing; Procedure: fatigue assessment and management; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Wales Cancer Trials Unit
Recruiting - verified September 2010 - Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsors: Wales Cancer Trials Unit; Wales Cancer Trials Unit; Cardiff University
Recruiting - verified March 2012 - Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010 - Conditions: Leukemia; Mucositis; Oral Complications
Interventions: Biological: palifermin; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011 - Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: quality-of-life assessment; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Wales Cancer Trials Unit
Recruiting - verified May 2011 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: multikinase inhibitor AT9283; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Prostate Cancer
Interventions: Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: computed tomography; Procedure: magnetic resonance imaging; Procedure: single photon emission computed tomography; Radiation: technetium Tc 99m demobesin-4
Sponsors: Cancer Research UK; Cancer Research UK
Terminated - verified February 2012 - Conditions: Prostate Cancer; Sexual Dysfunction
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: high-intensity focused ultrasound ablation; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified May 2011 - Conditions: Graft Versus Host Disease; Nonneoplastic Condition
Interventions: Biological: adoptive immunotherapy; Biological: alemtuzumab; Biological: in vitro-treated peripheral blood lymphocyte therapy; Drug: foscarnet sodium; Drug: ganciclovir; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: infection prophylaxis and management; Procedure: peripheral blood stem cell transplantation; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospital Birmingham
Recruiting - verified April 2010 - Condition: Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); Institute of Cancer Research, United Kingdom
Recruiting - verified August 2009 - Condition: Hematopoietic/Lymphoid Cancer
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Recruiting - verified April 2010 - Condition: Ovarian Cancer
Interventions: Genetic: DNA methylation analysis; Genetic: microarray analysis; Genetic: polymerase chain reaction; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Scottish Gynaecological Cancer Study Group
Recruiting - verified July 2009 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Genetic: molecular genetic technique; Other: mass spectrometry; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide phosphate; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Sarcoma
Interventions: Genetic: microarray analysis; Genetic: molecular diagnostic method; Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Christie Hospital NHS Foundation Trust
Recruiting - verified April 2008 - Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis; Genetic: mutation analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method; Procedure: sentinel lymph node biopsy
Sponsors: National Cancer Institute (NCI); Leeds Cancer Centre at St. James's University Hospital
Recruiting - verified April 2008 - Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Institute of Cancer Research, United Kingdom
Active, not recruiting - verified March 2009 - Conditions: Malignant Mesothelioma; Metastatic Cancer
Interventions: Other: talc; Procedure: therapeutic thoracoscopy; Procedure: therapeutic videothoracoscopy
Sponsors: Papworth Hospital NHS Foundation Trust; Papworth Hospital NHS Foundation Trust
Active, not recruiting - verified March 2012 - Condition: Osteoarthritis, Knee
Intervention: Device: pneumatic brace
Sponsors: The New England Baptist Hospital; The New England Baptist Hospital; Boston University; Spaulding Rehabilitation Hospital
Completed - verified July 2011 - Condition: Leukemia
Interventions: Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: fludarabine phosphate; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: protein expression analysis; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified January 2009 - Condition: Healthy
Intervention: Drug: Filgrastim
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified February 2012 - Condition: Pulmonary Embolism
Interventions: Drug: warfarin; Drug: Fondaparinux:; Drug: warfarin
Sponsors: The New England Baptist Hospital; The New England Baptist Hospital
Active, not recruiting - verified September 2011 - Condition: Breast Cancer
Interventions: Drug: abiraterone acetate; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified April 2012 - Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Leeds Cancer Centre at St. James's University Hospital
Recruiting - verified June 2009 - Condition: Head and Neck Cancer
Interventions: Procedure: positron emission tomography/computed tomography; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Warwick Medical School
Recruiting - verified December 2008 - Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: parenteral chemotherapy
Sponsors: National Cancer Institute (NCI); Warwick Medical School
Recruiting - verified November 2008 - Condition: Choroidal Melanoma
Intervention: Procedure: Ranibizumab injection and TTT - ICG based
Sponsors: New England Retina Associates; New England Retina Associates
Active, not recruiting - verified August 2011 - Conditions: Lymphoma; Neurotoxicity
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisolone; Drug: procarbazine hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Recruiting - verified January 2009 - Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Ovarian Cancer
Interventions: Drug: rucaparib (CO-338; formally AG-014699 or PF-01367338); Genetic: protein expression analysis; Genetic: western blotting; Other: immunohistochemistry staining method; Other: liquid chromatography; Other: mass spectrometry; Other: pharmacological study
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Medical Research Council; Cheryl Pugh
Active, not recruiting - verified February 2012 - Conditions: Anxiety Disorder; Long-term Effects Secondary to Cancer Therapy in Adults; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: cyproterone acetate; Drug: releasing hormone agonist therapy; Other: active surveillance; Other: medical chart review; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery; Procedure: therapeutic lymphadenectomy; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Oxford Radcliffe Hospital
Active, not recruiting - verified October 2011 - Effects Of Invasive And Noninvasive Mechanical Ventilation On Sleep In The Intensive Care Unit (ICU)Conditions: Respiratory Insufficiency; Respiration, Artificial; Sleep Deprivation
Intervention:
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified July 2011 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Genetic: DNA methylation analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; Radiation Therapy Oncology Group; Medical Research Council; Cooperative Trials Group for Neuro-Oncology
Recruiting - verified May 2011 - Magnetic Resonance Imaging and Computed Tomography in Patients With Stage I Seminoma of the TesticleCondition: Testicular Germ Cell Tumor
Interventions: Other: questionnaire administration; Procedure: computed tomography; Procedure: magnetic resonance imaging; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: Head and Neck Cancer
Interventions: Other: questionnaire administration; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment; Procedure: regional lymph node dissection; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); The Facial Surgery Research Foundation
Recruiting - verified July 2009 - Condition: Colorectal Cancer
Interventions: Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Completed - verified August 2009 - Condition: Colorectal Cancer
Interventions: Other: laboratory biomarker analysis; Procedure: computed tomography; Procedure: magnetic resonance imaging; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southampton University Hospitals NHS Trust
Recruiting - verified August 2009 - Condition: Breast Cancer
Interventions: Drug: Letrozole; Drug: Letrozole
Sponsors: International Breast Cancer Study Group; International Breast Cancer Study Group
Recruiting - verified March 2012 - Condition: Testicular Germ Cell Tumor
Interventions: Other: biomarker analysis; Procedure: computed tomography
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified October 2007 - Conditions: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction; Urinary Complications
Interventions: Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified July 2009 - Condition: HIV Infections
Interventions: Drug: Darunavir (DRV/r); Drug: continue on current dual boosted PI
Sponsors: Community Research Initiative of New England; Community Research Initiative of New England
Completed - verified February 2012 - Condition: Breast Cancer
Interventions: Genetic: gene expression analysis; Genetic: molecular diagnostic method; Genetic: polymorphism analysis; Genetic: protein expression analysis; Other: medical chart review; Other: questionnaire administration
Sponsors: National Cancer Institute (NCI); National Cancer Research Network
Recruiting - verified September 2007 - Conditions: Lung Cancer; Thromboembolism
Interventions: Drug: dalteparin; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Velindre NHS Trust
Recruiting - verified March 2008 - Condition: Breast Cancer
Interventions: Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: epirubicin hydrochloride; Genetic: proteomic profiling; Other: diagnostic laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: pharmacological study; Other: surface-enhanced laser desorption/ionization-time of flight mass spectrometry; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Charing Cross Hospital
Recruiting - verified September 2007 - CYP3A5 Gene as a Risk Factor for Kidney Damage in Young Patients With Cancer Treated With IfosfamideConditions: Chemotherapeutic Agent Toxicity; Sarcoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Genetic: gene expression analysis; Genetic: polymorphism analysis; Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: motexafin gadolinium; Drug: temozolomide; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Recruiting - verified June 2009 - Conditions: Lung Cancer; Precancerous Condition
Interventions: Other: cytology and cytometry specimen collection procedure; Other: Chest x ray; Procedure: Autofluorescence bronchoscopy; Procedure: CT scan
Sponsors: University College, London; University College, London
Completed - verified December 2011 - Condition: Malignant Mesothelioma
Interventions: Drug: bortezomib; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); All Ireland Cooperative Oncology Research Group
Recruiting - verified August 2007 - Condition: Kidney Cancer
Interventions: Drug: sorafenib tosylate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2008 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: paclitaxel; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified April 2012 - Conditions: Colorectal Cancer; Metastatic Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: study of socioeconomic and demographic variables; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Southampton University Hospitals NHS Trust
Recruiting - verified April 2008 - Conditions: Pancreatic Cancer; Thromboembolism
Interventions: Drug: dalteparin; Drug: gemcitabine hydrochloride; Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Hull and East Yorkshire Hospitals NHS Trust
Recruiting - verified April 2007 - Conditions: Graft Versus Host Disease; Infection; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Genetic: polymerase chain reaction; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); St. Bartholomew's Hospital
Recruiting - verified September 2007 - Conditions: Breast Cancer; Hypercalcemia of Malignancy; Metastatic Cancer; Musculoskeletal Complications; Pain
Interventions: Drug: zoledronic acid; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University of Leeds
Recruiting - verified November 2007 - Conditions: Leukemia; Myelodysplastic Syndromes
Interventions: Biological: alemtuzumab; Drug: arsenic trioxide; Drug: azacitidine; Drug: busulfan; Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: fludarabine phosphate; Drug: gemtuzumab ozogamicin; Drug: melphalan; Drug: tipifarnib; Genetic: DNA methylation analysis; Genetic: cytogenetic analysis; Genetic: gene expression analysis; Genetic: mutation analysis; Other: diagnostic laboratory biomarker analysis; Other: immunologic technique; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); The University of New South Wales
Recruiting - verified August 2008 - Condition: Oesophagogastric Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cisplatin; Drug: epirubicin hydrochloride; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: Medical Research Council; Professor David Cunningham; Cancer Research UK
Recruiting - verified January 2012 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: pravastatin sodium
Sponsors: University College, London; University College, London
Recruiting - verified December 2011 - Conditions: Breast Cancer; Infertility; Menopausal Symptoms
Interventions: Drug: cyclophosphamide; Drug: goserelin acetate; Procedure: adjuvant therapy; Procedure: fertility assessment and management; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Anglo Celtic Cooperative Oncology Group
Recruiting - verified May 2007 - Condition: Pancreatic Cancer
Interventions: Biological: sargramostim; Biological: telomerase peptide vaccine GV1001; Drug: capecitabine; Drug: gemcitabine hydrochloride
Sponsors: National Cancer Institute (NCI); Royal Liverpool University Hospital
Recruiting - verified May 2009 - Condition: Sarcoma
Interventions: Procedure: adjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer Research Campaign Clinical Trials Centre
Recruiting - verified December 2007 - Conditions: Multiple Myeloma and Plasma Cell Neoplasm; Renal Failure
Interventions: Drug: chemotherapy; Drug: dexamethasone; Procedure: plasmapheresis
Sponsors: National Cancer Institute (NCI); University of Glasgow
Recruiting - verified June 2007 - Condition: HIV Infections
Interventions: Drug: efavirenz; Drug: tenofovir; Drug: emtricitabine
Sponsors: Community Research Initiative of New England; Community Research Initiative of New England; The Campbell Foundation
Completed - verified February 2012 - Conditions: Lung Cancer; Metastatic Cancer
Interventions: Drug: dexamethasone; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified January 2007 - Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: capecitabine; Other: clinical observation; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Southampton University Hospitals NHS Trust
Recruiting - verified October 2011 - Condition: Lung Cancer
Interventions: Drug: Control arm (SEQ):; Drug: Experimental arm (CON):
Sponsors: University College, London; University College, London
Active, not recruiting - verified March 2012 - Conditions: Anemia; Cardiovascular Complications; Hot Flashes; Osteoporosis; Prostate Cancer
Interventions: Drug: releasing hormone agonist therapy; Drug: transdermal estrogen
Sponsors: National Cancer Institute (NCI); Imperial College London
Recruiting - verified June 2008 - Conditions: Extragonadal Germ Cell Tumor; Teratoma; Testicular Germ Cell Tumor
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified May 2007 - Condition: Lymphoma
Interventions: Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: pharmacological study; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); German High-Grade Non-Hodgkin's Lymphoma Study Group
Recruiting - verified March 2010 - Condition: Lichen Planus
Intervention: Drug: Etanercept
Sponsors: Stanford University; Stanford University; Wright State University; Tufts Medical Center; University of Louisville; Wake Forest University; University of Michigan; Emory University; University Hospitals of Cleveland; Mount Sinai School of Medicine; Oregon Health and Science University; The Cleveland Clinic; Fivenson, David, M.D.
Completed - verified June 2011 - Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: etoposide; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Cancer and Leukaemia Group
Active, not recruiting - verified February 2006 - Condition: Childhood Langerhans Cell Histiocytosis
Interventions: Drug: leucovorin calcium; Drug: methotrexate; Drug: prednisolone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Histiocyte Society
Recruiting - verified May 2007 - Condition: Prostate Cancer
Interventions: Drug: celecoxib; Drug: docetaxel; Drug: prednisolone; Drug: releasing hormone agonist therapy; Drug: zoledronic acid; Drug: abiraterone; Procedure: orchiectomy
Sponsors: Medical Research Council; Medical Research Council
Recruiting - verified March 2012 - Condition: Malignant Mesothelioma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified November 2006 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Radiation: radiation therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC; NCIC Clinical Trials Group; British Medical Research Council; Trans-Tasman Radiation Oncology Group (TROG)
Active, not recruiting - verified February 2012 - Condition: Hypercholesterolemia
Intervention: Behavioral: Soy protein
Sponsors: Tufts University; Tufts University
Completed - verified November 2011 - Conditions: Metastatic Cancer; Pain; Prostate Cancer
Intervention: Drug: ibandronate sodium
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Completed - verified June 2009 - Condition: Breast Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: proteomic profiling; Other: cytology specimen collection procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: breast duct lavage
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified December 2005 - Condition: Breast Cancer
Interventions: Genetic: cytogenetic analysis; Genetic: proteomic profiling; Other: cytology specimen collection procedure; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: breast duct lavage
Sponsors: National Cancer Institute (NCI); Royal Marsden NHS Foundation Trust
Recruiting - verified December 2005 - Condition: Breast Cancer
Intervention: Drug: anastrozole
Sponsors: Queen Mary University of London; Jill Knox
Active, not recruiting - verified April 2012 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Royal College of Obstetricians and Gynecologists
Recruiting - verified May 2007 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Drug: Anastrozole
Sponsors: Queen Mary University of London; Jill Knox; Cancer Research UK
Active, not recruiting - verified May 2012 - Condition: Colorectal Cancer
Interventions: Drug: FOLFOX regimen; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); University of Leeds; Medical Research Council
Active, not recruiting - verified June 2011 - Condition: Lung Cancer
Interventions: Drug: Carboplatin, etoposide & thalidomide; Drug: Carboplatin, etoposide & placebo
Sponsors: University College, London; University College, London
Completed - verified March 2012 - Condition: Kidney Cancer
Interventions: Biological: dactinomycin; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; Societe Francaise Oncologie Pediatrique; Children's Cancer and Leukaemia Group; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
Recruiting - verified June 2009 - Condition: Esophageal Cancer
Interventions: Drug: cisplatin; Drug: epirubicin hydrochloride; Drug: fluorouracil; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Recruiting - verified March 2007 - Condition: Cervical Cancer
Interventions: Procedure: conventional surgery; Procedure: neoadjuvant chemotherapy; Radiation: brachytherapy; Radiation: radiation therapy; Drug: cisplatin
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Recruiting - verified March 2012 - Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified March 2007 - Condition: Neuroblastoma
Interventions: Biological: filgrastim; Biological: monoclonal antibody Ch14.18; Drug: busulfan; Drug: carboplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: melphalan; Drug: vincristine sulfate; Procedure: bone marrow ablation with stem cell support; Procedure: conventional surgery; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester
Recruiting - verified August 2010 - Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Anal Cancer
Interventions: Drug: cisplatin; Drug: fluorouracil; Drug: mitomycin C; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University College London (UCL) Cancer Institute
Recruiting - verified March 2007 - Condition: Bladder Cancer
Interventions: Drug: fluorouracil; Drug: mitomycin C; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospital Birmingham
Active, not recruiting - verified May 2007 - Condition: Breast Cancer
Interventions: Biological: filgrastim; Drug: cyclophosphamide; Drug: docetaxel; Drug: epirubicin hydrochloride; Drug: fluorouracil; Genetic: microarray analysis; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Swedish Breast Cancer Group; Swiss Group for Clinical Cancer Research; Anglo Celtic Cooperative Oncology Group
Active, not recruiting - verified January 2010 - Condition: Colorectal Cancer
Interventions: Drug: FOLFIRI regimen; Drug: FOLFOX regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Medical Research Council
Active, not recruiting - verified March 2002 - Condition: Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: leucovorin calcium; Drug: methotrexate; Drug: therapeutic hydrocortisone; Drug: vinblastine sulfate
Sponsors: National Cancer Institute (NCI); Institut Gustave Roussy
Active, not recruiting - verified August 2011 - Condition: Lymphoma
Interventions: Drug: chlorambucil; Drug: dexamethasone; Drug: fludarabine phosphate; Drug: mitoxantrone hydrochloride
Sponsors: National Cancer Institute (NCI); Lymphoma Trials Office
Active, not recruiting - verified March 2007 - Condition: Melanoma (Skin)
Interventions: Biological: pegylated interferon alfa; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified October 2000 - Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: rebimastat
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified August 2011 - Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); British Association of Surgical Oncology: Breast Group
Active, not recruiting - verified December 2006 - Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: thalidomide
Sponsors: National Cancer Institute (NCI); Cancer Research UK
Recruiting - verified November 2011 - Condition: Leukemia
Interventions: Drug: chlorambucil; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: fludarabine phosphate; Drug: prednisolone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Leukemia Research Fund; Medical Research Council
Active, not recruiting - verified January 2006 - Condition: Breast Cancer
Interventions: Drug: cyclophosphamide; Drug: epirubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Medical Research Council
Active, not recruiting - verified December 2005 - Conditions: Extragonadal Germ Cell Tumor; Teratoma; Testicular Germ Cell Tumor
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: cisplatin; Drug: etoposide; Drug: paclitaxel
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012 - Condition: Neuroblastoma
Intervention: Procedure: surgical procedure
Sponsors: National Cancer Institute (NCI); Societe Internationale d'Oncologie Pediatrique
Recruiting - verified July 2007 - Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified March 2012 - Condition: Sarcoma
Interventions: Drug: doxorubicin hydrochloride; Drug: ifosfamide
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Completed - verified January 2012 - Condition: Brain and Central Nervous System Tumors
Interventions: Drug: lomustine; Drug: procarbazine hydrochloride; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC; Medical Research Council
Active, not recruiting - verified November 2011 - Condition: Melanoma (Skin)
Intervention: Biological: recombinant interferon alfa
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified November 2011 - Condition: Endometrial Cancer
Interventions: Procedure: adjuvant therapy; Procedure: conventional surgery; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Medical Research Council
Active, not recruiting - verified April 1999 - Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group
Completed - verified September 2011 - Condition: Lymphoma
Intervention: Biological: recombinant interferon alfa
Sponsors: National Cancer Institute (NCI); Lymphoma Study Association
Active, not recruiting - verified May 2007 - Condition: Lymphoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: mitoxantrone hydrochloride; Drug: prednisolone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified May 2007 - Condition: Breast Cancer
Intervention: Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Institute of Cancer Research, United Kingdom
Active, not recruiting - verified July 2011 - Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: low-LET cobalt-60 gamma ray therapy; Radiation: low-LET electron therapy; Radiation: low-LET photon therapy
Sponsors: National Cancer Institute (NCI); European Organization for Research and Treatment of Cancer - EORTC
Active, not recruiting - verified May 2007 - Condition: Lung Cancer
Interventions: Biological: BCG vaccine; Biological: monoclonal antibody BEC2
Sponsors: European Organization for Research and Treatment of Cancer - EORTC; European Organization for Research and Treatment of Cancer - EORTC
Completed - verified March 2012
 |
Join Clinical Trials by University in England, United Kingdom |
